Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Generic Central Nervous System Drug Market Report. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


Generic Central Nervous System Drug Trends and Forecast

The future of the global generic central nervous system drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global generic central nervous system drug market is expected to grow with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising prevalence of mental health disorders, expanding government initiatives for mental health awareness, and increasing usage of 3D printing for drug manufacturing.
Generic Central Nervous System Drug Trends and Forecast

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Generic Central Nervous System Drug by Segment

Generic Central Nervous System Drug by Segment

The study includes a forecast for the global generic central nervous system drug by type, disease, drug classification, mode of purchase, and region.

Generic Central Nervous System Drug Market by Type [Shipment Analysis by Value from 2018 to 2030]:


• Multiple Sclerosis
• Anti-Psychotic
• Analgesics
• Anti-Parkinson Drugs
• Anesthetics
• Anti-Epileptics
• Anti-Depressants
• Others

Generic Central Nervous System Drug Market by Disease [Shipment Analysis by Value from 2018 to 2030]:


• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Infectious Diseases
• CNS Cancer

Generic Central Nervous System Drug Market by Drug Classification [Shipment Analysis by Value from 2018 to 2030]:


• Branded Drugs
• Generic Drugs

Generic Central Nervous System Drug Market by Mode of Purchase [Shipment Analysis by Value from 2018 to 2030]:


• Over-The-Counter Drugs
• Prescription-Based Drugs

Generic Central Nervous System Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:


• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Generic Central Nervous System Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies generic central nervous system drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the generic central nervous system drug companies profiled in this report include-
• Biogen
• Johnson & Johnson
• Hoffmann-La Roche
• Novartis
• UCB
• Sanofi
• Pfizer
• Merck
• Sumitomo Dainippon Pharma
• AbbVie

Generic Central Nervous System Drug Market Insights

Lucintel forecasts that anti-depressants is expected to witness highest growth over the forecast period.
Within this market, generic drugs is expected to witness higher growth over the forecast period.
North America is expected to witness highest growth over the forecast period.

Features of the Global Generic Central Nervous System Drug Market

Market Size Estimates: Generic central nervous system drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Generic central nervous system drug market size by various segments, such as by type, disease, drug classification, mode of purchase, and region in terms of value ($B).
Regional Analysis: Generic central nervous system drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, diseases, drug classifications, mode of purchases, and regions for the generic central nervous system drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the generic central nervous system drug market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for generic central nervous system drug market?
Answer: The global generic central nervous system drug market is expected to grow with a CAGR of 6.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the generic central nervous system drug market?
Answer: The major drivers for this market are rising prevalence of mental health disorders, expanding government initiatives for mental health awareness, and increasing usage of 3D printing for drug manufacturing.
Q3. What are the major segments for generic central nervous system drug market?
Answer: The future of the generic central nervous system drug market looks promising with opportunities in the branded drugs and generic drugs markets.
Q4. Who are the key generic central nervous system drug market companies?
Answer: Some of the key generic central nervous system drug companies are as follows:
• Biogen
• Johnson & Johnson
• Hoffmann-La Roche
• Novartis
• UCB
• Sanofi
• Pfizer
• Merck
• Sumitomo Dainippon Pharma
• AbbVie
Q5. Which generic central nervous system drug market segment will be the largest in future?
Answer: Lucintel forecasts that anti-depressants is expected to witness highest growth over the forecast period.
Q6. In generic central nervous system drug market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the generic central nervous system drug market by type (multiple sclerosis, anti-psychotic, analgesics, anti-parkinson drugs, anesthetics, anti-epileptics, anti-depressants, and others), disease (neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and CNS cancer), drug classification (branded drugs and generic drugs), mode of purchase (over-the-counter drugs and prescription-based drugs), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

For any questions related to Generic Central Nervous System Drug Market, Generic Central Nervous System Drug Market Size, Generic Central Nervous System Drug Market Growth, Generic Central Nervous System Drug Market Analysis, Generic Central Nervous System Drug Market Report, Generic Central Nervous System Drug Market Share, Generic Central Nervous System Drug Market Trends, Generic Central Nervous System Drug Market Forecast, Generic Central Nervous System Drug Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents

1. Executive Summary
2. Global Generic Central Nervous System Drug Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Generic Central Nervous System Drug Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Generic Central Nervous System Drug Market by Type
3.3.1: Multiple Sclerosis
3.3.2: Anti-Psychotic
3.3.3: Analgesics
3.3.4: Anti-Parkinson Drugs
3.3.5: Anesthetics
3.3.6: Anti-Epileptics
3.3.7: Anti-Depressants
3.3.8: Others
3.4: Global Generic Central Nervous System Drug Market by Disease
3.4.1: Neurovascular Diseases
3.4.2: CNS Trauma
3.4.3: Mental Health
3.4.4: Neurodegenerative Diseases
3.4.5: Infectious Diseases
3.4.6: CNS Cancer
3.5: Global Generic Central Nervous System Drug Market by Drug Classification
3.5.1: Branded Drugs
3.5.2: Generic Drugs
3.6: Global Generic Central Nervous System Drug Market by Mode of Purchase
3.6.1: Over-The-Counter Drugs
3.6.2: Prescription-Based Drugs
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Generic Central Nervous System Drug Market by Region
4.2: North American Generic Central Nervous System Drug Market
4.2.1: North American Generic Central Nervous System Drug Market by Type: Multiple Sclerosis, Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, and Others
4.2.2: North American Generic Central Nervous System Drug Market by Drug Classification: Branded Drugs and Generic Drugs
4.3: European Generic Central Nervous System Drug Market
4.3.1: European Generic Central Nervous System Drug Market by Type: Multiple Sclerosis, Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, and Others
4.3.2: European Generic Central Nervous System Drug Market by Drug Classification: Branded Drugs and Generic Drugs
4.4: APAC Generic Central Nervous System Drug Market
4.4.1: APAC Generic Central Nervous System Drug Market by Type: Multiple Sclerosis, Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, and Others
4.4.2: APAC Generic Central Nervous System Drug Market by Drug Classification: Branded Drugs and Generic Drugs
4.5: ROW Generic Central Nervous System Drug Market
4.5.1: ROW Generic Central Nervous System Drug Market by Type: Multiple Sclerosis, Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, and Others
4.5.2: ROW Generic Central Nervous System Drug Market by Drug Classification: Branded Drugs and Generic Drugs
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Generic Central Nervous System Drug Market by Type
6.1.2: Growth Opportunities for the Global Generic Central Nervous System Drug Market by Disease
6.1.3: Growth Opportunities for the Global Generic Central Nervous System Drug Market by Drug Classification
6.1.4: Growth Opportunities for the Global Generic Central Nervous System Drug Market by Mode of Purchase
6.1.5: Growth Opportunities for the Global Generic Central Nervous System Drug Market by Region
6.2: Emerging Trends in the Global Generic Central Nervous System Drug Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Generic Central Nervous System Drug Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Generic Central Nervous System Drug Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Biogen
7.2: Johnson & Johnson
7.3: Hoffmann-La Roche
7.4: Novartis
7.5: UCB
7.6: Sanofi
7.7: Pfizer
7.8: Merck
7.9: Sumitomo Dainippon Pharma
7.10: AbbVie
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Generic Central Nervous System Drug Market Report: Trends, Forecast and Competitive Analysis to 2030 Full Report $ 4,850
A 150 Page Report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Generic Central Nervous System Drug Market Report.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )